Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Moksha8 Pharmaceuticals.

    Client Virtual Booth

    MOKSHA8 PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Moksha8 Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1055 Westlakes Dr, Berwyn, PA 19312
    Telephone
    Telephone
    +16107274018
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://moksha8.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/moksha8/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Agreement with SERB Pharmaceuticals to Bring Voraxaze® (glucarpidase) to Latin America

    Details:

    M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.


    Lead Product(s): Glucarpidase

    Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: SERB Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 20, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogli...

    Details:

    Under the agreement, M8 will have the rights to register and commercialize Envlo™ (enavogliflozin) for Brazil and Mexico. Envlo™ is a SGLT2 (sodium glucose cotransporter 2) inhibitor type diabetes treatment.


    Lead Product(s): Enavogliflozin

    Therapeutic Area: Endocrinology Product Name: Envlo

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Daewoong Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico

    Details:

    According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.


    Lead Product(s): Piracetam

    Therapeutic Area: Neurology Product Name: Nootropil

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: UCB Pharma S.A

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership June 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico

    Details:

    The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.


    Lead Product(s): Methylphenidate

    Therapeutic Area: Psychiatry/Psychology Product Name: Concerta

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search